Pharmacolog chooses to adjust its current sales strategy to invest more in direct sales resources via its own subsidiaries and strategic partnerships. The company has previously announced that it has terminated the cooperation with Pharmed SAM and establishing its own company in France. One consequence of the changed strategy is that the current sales manager leaves the company.
The company has decided to partially change its current sales strategy to invest more in direct sales resources in its key markets in the US and France. One consequence of this is that the company now forms its own subsidiary in France and employs its own sales resources. The recruitment of additional salespeople in the US has also just begun. In addition to investing in our own sales resources, further focus will be placed on seeking collaborations with strategic partners in the North American market as well. To relieve the CEO, a CFO will be hired. One consequence of the changed strategy is that the current sales manager leaves the company on April 30.
Mats Högberg, CEO, comments: “After analysis, we have decided to focus more on the markets where we have important reference installations, and which also have the greatest potential. That is why we form our own company in France and employ our own sales resources. In the US, we have just initiated the recruitment of another salesperson with a location on the East Coast. In combination with the investment in our own sales resources in key markets, we will focus further on establishing strategic partnerships with major players in the industry. The interest in our technology is strong and our solutions fit well into several of the larger companies’ more comprehensive solutions for more efficient and safer drug management.”
This information is insider information that Pharmacolog AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on January 13th, at 10:00.
About Pharmacolog AB
Pharmacolog is specialized in developing systems and solutions for more effective and safer use of intravenous drugs. The company’s first product, DrugLog®, enables a nurse or pharmacist to quickly and easily verify that an injectable drug has the right identity and concentration. Pharmacolog’s long-term vision is an individually optimized medication for each individual patient, considering all available parameters in the control and distribution of the drug. Further information regarding the company is available at http://www.pharmacolog.com. The company’s Certified Adviser is Mangold Fondkommission AB, which can be reached on telephone number +46 8-5030 15 50 or through CA@mangold.se.